Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-blind, Placebo-controlled, Parallel Group, Multicenter Phase 2a Study to Explore the Efficacy and Safety of Tezepelumab in Patients With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) (COURSE)

Next Previous
X
Search
Trial Profile

A Randomized, Double-blind, Placebo-controlled, Parallel Group, Multicenter Phase 2a Study to Explore the Efficacy and Safety of Tezepelumab in Patients With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) (COURSE)

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 20 Feb 2025

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tezepelumab (Primary)
  • Indications Chronic obstructive pulmonary disease
  • Focus Proof of concept; Therapeutic Use
  • Acronyms COURSE
  • Sponsors AstraZeneca; AstraZeneca AB

    • Most Recent Events

    • 06 Aug 2024 According to an Amgen Media Release, the FDA granted TEZSPIRE Breakthrough Therapy Designation as an add-on maintenance treatment of patients with moderate to very severe COPD characterized by an eosinophilic phenotype, based on results from this trial.
    • 22 May 2024 Results of Efficacy and Safety of Tezepelumab , presented at the 120th International Conference of the American Thoracic Society
    • 19 May 2024 Primary endpoint (Moderate or severe COPD exacerbation rate ratio (tezepelumab vs placebo)) has not been met, according to an AstraZeneca Media Release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top